Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 347

1.

Mandatory employee vaccination as a strategy for early and comprehensive health care personnel immunization coverage: Experience from 10 influenza seasons.

Blank C, Gemeinhart N, Dunagan WC, Babcock HM.

Am J Infect Control. 2020 Mar 29. pii: S0196-6553(20)30042-0. doi: 10.1016/j.ajic.2020.01.015. [Epub ahead of print]

PMID:
32238270
2.

Lactate dehydrogenase: a marker of diminished antitumor immunity.

Van Wilpe S, Koornstra R, Den Brok M, De Groot JW, Blank C, De Vries J, Gerritsen W, Mehra N.

Oncoimmunology. 2020 Feb 26;9(1):1731942. doi: 10.1080/2162402X.2020.1731942. eCollection 2020. Review.

3.

Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry.

Verheijden RJ, May AM, Blank CU, Aarts MJB, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, Boers-Sonderen MJ, van der Hoeven JJM, Hospers GA, Piersma D, van Rijn RS, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van Zeijl MCT, Wouters MWJM, Haanen JBAG, Kapiteijn E, Suijkerbuijk KPM.

Clin Cancer Res. 2020 Jan 27. doi: 10.1158/1078-0432.CCR-19-3322. [Epub ahead of print]

PMID:
31988197
4.

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.

Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R, Mezzadra R, Gomez-Eerland R, Yildiz M, Dagidir I, Apriamashvili G, Zandhuis N, van der Noort V, Visser NL, Blank CU, Altelaar M, Schumacher TN, Peeper DS.

Cell. 2020 Jan 23;180(2):404-405. doi: 10.1016/j.cell.2020.01.005. No abstract available.

PMID:
31978349
5.

Return to Sports after Anterior Cruciate Ligament Injury: a Matched-Pair Analysis of Repair with Internal Brace and Reconstruction Using Hamstring or Quadriceps Tendons.

Ortmaier R, Fink C, Schobersberger W, Kindermann H, Leister I, Runer A, Hepperger C, Blank C, Mattiassich G.

Sportverletz Sportschaden. 2020 Jan 23. doi: 10.1055/a-1019-0949. [Epub ahead of print]

PMID:
31975356
6.

Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.

de Bruijn R, Wimalasingham A, Szabados B, Stewart GD, Welsh SJ, Kuusk T, Blank C, Haanen J, Klatte T, Staehler M, Powles T, Bex A.

Eur Urol Oncol. 2020 Jan 16. pii: S2588-9311(20)30001-8. doi: 10.1016/j.euo.2019.12.004. [Epub ahead of print]

PMID:
31956080
7.

B cells and tertiary lymphoid structures promote immunotherapy response.

Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA.

Nature. 2020 Jan;577(7791):549-555. doi: 10.1038/s41586-019-1922-8. Epub 2020 Jan 15.

PMID:
31942075
8.

Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.

Ugurel S, Schadendorf D, Horny K, Sucker A, Schramm S, Utikal J, Pföhler C, Herbst R, Schilling B, Blank C, Becker JC, Paschen A, Zimmer L, Livingstone E, Horn PA, Rebmann V.

Ann Oncol. 2020 Jan;31(1):144-152. doi: 10.1016/j.annonc.2019.09.005.

PMID:
31912789
9.

Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM).

Rozeman EA, Prevoo W, Meier MAJ, Sikorska K, Van TM, van de Wiel BA, van der Wal JE, Mallo HA, Grijpink-Ongering LG, Broeks A, Lalezari F, Reeves J, Warren S, van Thienen JV, van Tinteren H, Haanen JBAG, Kapiteijn E, Blank CU.

Melanoma Res. 2020 Jan 21. doi: 10.1097/CMR.0000000000000653. [Epub ahead of print]

PMID:
31895753
10.

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.

Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S.

JAMA Oncol. 2020 Jan 2. doi: 10.1001/jamaoncol.2019.5570. [Epub ahead of print]

11.

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

Hauschild A, Ascierto PA, Schadendorf D, Grob JJ, Ribas A, Kiecker F, Dutriaux C, Demidov LV, Lebbé C, Rutkowski P, Blank CU, Gutzmer R, Millward M, Kefford R, Haas T, D'Amelio A Jr, Gasal E, Mookerjee B, Chapman PB.

Eur J Cancer. 2020 Jan;125:114-120. doi: 10.1016/j.ejca.2019.10.033.

PMID:
31864178
12.

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Amon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, Elmarakeby H, Dietlein F, Miao D, Tracy A, Gogas H, Goldinger SM, Utikal J, Blank CU, Rauschenberg R, von Bubnoff D, Krackhardt A, Weide B, Haferkamp S, Kiecker F, Izar B, Garraway L, Regev A, Flaherty K, Paschen A, Van Allen EM, Schadendorf D.

Nat Med. 2019 Dec;25(12):1916-1927. doi: 10.1038/s41591-019-0654-5. Epub 2019 Dec 2.

13.

Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.

Reijers ILM, Rozeman EA, Wilgenhof S, van Thienen JV, Haanen JBAG, Blank CU.

Pigment Cell Melanoma Res. 2019 Oct 23. doi: 10.1111/pcmr.12835. [Epub ahead of print]

PMID:
31646741
14.

Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations.

Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, de Groot JWB, van der Veldt AAM, Johnson DB, Meiss F, Schlaak M, Schilling B, Westgeest HM, Gutzmer R, Pföhler C, Meier F, Zimmer L, Suijkerbuijk KPM, Haalck T, Thoms KM, Herbschleb K, Leichsenring J, Menzer A, Kopp-Schneider A, Long GV, Kefford R, Enk A, Blank CU, Hassel JC.

J Clin Oncol. 2019 Nov 20;37(33):3142-3151. doi: 10.1200/JCO.19.00489. Epub 2019 Oct 3.

PMID:
31580757
15.

Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy.

Renner K, Bruss C, Schnell A, Koehl G, Becker HM, Fante M, Menevse AN, Kauer N, Blazquez R, Hacker L, Decking SM, Bohn T, Faerber S, Evert K, Aigle L, Amslinger S, Landa M, Krijgsman O, Rozeman EA, Brummer C, Siska PJ, Singer K, Pektor S, Miederer M, Peter K, Gottfried E, Herr W, Marchiq I, Pouyssegur J, Roush WR, Ong S, Warren S, Pukrop T, Beckhove P, Lang SA, Bopp T, Blank CU, Cleveland JL, Oefner PJ, Dettmer K, Selby M, Kreutz M.

Cell Rep. 2019 Oct 1;29(1):135-150.e9. doi: 10.1016/j.celrep.2019.08.068.

16.

Defining 'T cell exhaustion'.

Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, Schietinger A, Schumacher TN, Schwartzberg PL, Sharpe AH, Speiser DE, Wherry EJ, Youngblood BA, Zehn D.

Nat Rev Immunol. 2019 Nov;19(11):665-674. doi: 10.1038/s41577-019-0221-9. Epub 2019 Sep 30. Review.

PMID:
31570879
17.

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events.

Hoefsmit EP, Rozeman EA, Haanen JBAG, Blank CU.

ESMO Open. 2019 Jul 21;4(4):e000472. doi: 10.1136/esmoopen-2018-000472. eCollection 2019. Review.

18.

A conserved Mcm4 motif is required for Mcm2-7 double-hexamer formation and origin DNA unwinding.

Champasa K, Blank C, Friedman LJ, Gelles J, Bell SP.

Elife. 2019 Aug 6;8. pii: e45538. doi: 10.7554/eLife.45538.

19.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, Larkin JMG, Lorigan P, Neyns B, Blank CU, Petrella TM, Hamid O, Su SC, Krepler C, Ibrahim N, Long GV.

Lancet Oncol. 2019 Sep;20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2. Epub 2019 Jul 22.

PMID:
31345627
20.

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.

Jochems A, van der Kooij MK, Fiocco M, Schouwenburg MG, Aarts MJ, van Akkooi AC, van den Berkmortel FWPJ, Blank CU, van den Eertwegh AJM, Franken MG, de Groot JB, Haanen JBAG, Hospers GAP, Koornstra RH, Kruit WHJ, Louwman M, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl MCT, van der Hoeven KJM, Kapiteijn E.

Cancers (Basel). 2019 Jul 18;11(7). pii: E1007. doi: 10.3390/cancers11071007.

21.

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.

Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R, Mezzadra R, Gomez-Eerland R, Yildiz M, Dagidir I, Apriamashvili G, Zandhuis N, van der Noort V, Visser NL, Blank CU, Altelaar M, Schumacher TN, Peeper DS.

Cell. 2019 Jul 25;178(3):585-599.e15. doi: 10.1016/j.cell.2019.06.014. Epub 2019 Jul 11. Erratum in: Cell. 2020 Jan 23;180(2):404-405.

PMID:
31303383
22.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
23.

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L, van Melick HE, Aarts MJ, Lattouf JB, Powles T, De Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen JB, Bex A.

Eur Urol. 2019 Oct;76(4):437-440. doi: 10.1016/j.eururo.2019.06.006. Epub 2019 Jun 18.

PMID:
31227307
24.

Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.

Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, Utikal J, Haferkamp S, Blank C, Larkin J, Garbe C, Schadendorf D, Lorigan P, Schilling B.

Eur J Cancer. 2019 Jul;116:207-215. doi: 10.1016/j.ejca.2019.05.015. Epub 2019 Jun 15.

PMID:
31212163
25.

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jul;25(7):1175. doi: 10.1038/s41591-019-0520-5.

PMID:
31209337
26.

Compliance with needle-use declarations at two Olympic Winter Games: Sochi (2014) and PyeongChang (2018).

Schobersberger W, Blank C, Budgett R, Pipe A, Stuart MC.

Br J Sports Med. 2020 Jan;54(1):27-32. doi: 10.1136/bjsports-2018-100342. Epub 2019 Jun 15.

PMID:
31203198
27.

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suciu S, Robert C.

Eur J Cancer. 2019 Jul;116:148-157. doi: 10.1016/j.ejca.2019.05.020. Epub 2019 Jun 11.

PMID:
31200321
28.

Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors.

Rogiers A, Boekhout A, Schwarze JK, Awada G, Blank CU, Neyns B.

J Oncol. 2019 Apr 28;2019:5269062. doi: 10.1155/2019/5269062. eCollection 2019. Review.

29.

Combining checkpoint inhibition and targeted therapy in melanoma.

Rozeman EA, Blank CU.

Nat Med. 2019 Jun;25(6):879-882. doi: 10.1038/s41591-019-0482-7. No abstract available.

PMID:
31171877
30.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, Ter Meulen S, Koenen AM, Bosch LJW, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, Blank CU.

Lancet Oncol. 2019 Jul;20(7):948-960. doi: 10.1016/S1470-2045(19)30151-2. Epub 2019 May 31.

PMID:
31160251
31.

Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program.

Bisschop C, Wind TT, Blank CU, Koornstra RHT, Kapiteijn E, Van den Eertwegh AJM, De Groot JWB, Jalving M, Hospers GAP.

J Immunother. 2019 Jul/Aug;42(6):208-214. doi: 10.1097/CJI.0000000000000271.

PMID:
31145233
32.

Does Physical Activity during Alpine Vacations increase Tourists' Well-Being?

Schlemmer P, Blank C, Schnitzer M.

Int J Environ Res Public Health. 2019 May 15;16(10). pii: E1707. doi: 10.3390/ijerph16101707.

33.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13. Erratum in: Nat Med. 2019 Jun 17;:.

PMID:
31086347
34.

Feasibility of Ski Mountaineering for Patients Following a Total Knee Arthroplasty: A Descriptive Field Study.

Haslinger S, Huber D, Morawetz D, Blank C, Prossegger J, Dünnwald T, Koller A, Fink C, Hartl A, Schobersberger W.

Int J Environ Res Public Health. 2019 May 6;16(9). pii: E1582. doi: 10.3390/ijerph16091582.

35.

Colonization, Baker's law, and the evolution of gynodioecy in Hawaii: implications from a study of Lycium carolinianum.

Miller JS, Blank CM, Levin RA.

Am J Bot. 2019 May;106(5):733-743. doi: 10.1002/ajb2.1279. Epub 2019 May 1.

PMID:
31042317
36.

The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment.

O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL.

Clin Cancer Res. 2019 Oct 1;25(19):5743-5751. doi: 10.1158/1078-0432.CCR-18-2641. Epub 2019 Apr 30. Review.

PMID:
31040150
37.

A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX).

Bex A, van Thienen JV, Schrier M, Graafland N, Kuusk T, Hendricksen K, Lagerveld B, Zondervan P, van Moorselaar JA, Blank C, Wilgenhof S, Haanen J.

Future Oncol. 2019 Jul;15(19):2203-2209. doi: 10.2217/fon-2019-0111. Epub 2019 Apr 26. Erratum in: Future Oncol. 2019 Aug;15(22):2667.

PMID:
31023100
38.

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma.

van Herpen CML, Agarwala SS, Hauschild A, Berking C, Beck JT, Schadendorf D, Jansen R, Queirolo P, Ascierto PA, Blank CU, Heinrich MC, Pal RR, Derti A, Antona V, Nauwelaerts H, Zubel A, Dummer R.

Oncotarget. 2019 Mar 5;10(19):1850-1859. doi: 10.18632/oncotarget.26753. eCollection 2019 Mar 5.

39.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B.

Ann Oncol. 2019 Jul 1;30(7):1154-1161. doi: 10.1093/annonc/mdz110.

PMID:
30923820
40.

Sex-Related Differences After a Single Bout of Maximal Eccentric Exercise in Response to Acute Effects: A Systematic Review and Meta-analysis.

Morawetz D, Blank C, Koller A, Arvandi M, Siebert U, Schobersberger W.

J Strength Cond Res. 2019 Mar 15. doi: 10.1519/JSC.0000000000002867. [Epub ahead of print]

PMID:
30908366
41.

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.

Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Cǎlin AM, Delli Pizzi A, Lalezari F, Lambregts DMJ, Rohaan MW, Parmar C, Rozeman EA, Hartemink KJ, Swanton C, Haanen JBAG, Blank CU, Smit EF, Beets-Tan RGH, Aerts HJWL.

Ann Oncol. 2019 Jun 1;30(6):998-1004. doi: 10.1093/annonc/mdz108.

42.

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma.

Schermers B, Franke V, Rozeman EA, van de Wiel BA, Bruining A, Wouters MW, van Houdt WJ, Ten Haken B, Muller SH, Bierman C, Ruers TJM, Blank CU, van Akkooi ACJ.

Br J Surg. 2019 Apr;106(5):519-522. doi: 10.1002/bjs.11168. Epub 2019 Mar 18.

43.

Dedicated Ultrasound Speckle Tracking for Quantitative Analysis of Uterine Motion Outside Pregnancy.

Sammali F, Kuijsters NPM, Huang Y, Blank C, Rabotti C, Schoot BC, Mischi M.

IEEE Trans Ultrason Ferroelectr Freq Control. 2019 Mar;66(3):581-590. doi: 10.1109/TUFFC.2018.2867098.

PMID:
30872213
44.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B.

Cancer Immunol Immunother. 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26.

PMID:
30806748
45.

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma.

Wind TT, Jalving M, de Haan JJ, de Vries EGE, van Vugt MATM, Reijngoud DJ, van Rijn RS, Haanen JBAG, Blank CU, Hospers GAP, Fehrmann RSN.

Oncoimmunology. 2019 Jan 3;8(3):1558664. doi: 10.1080/2162402X.2018.1558664. eCollection 2019.

46.

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

Liu J, Rozeman EA, O'Donnell JS, Allen S, Fanchi L, Smyth MJ, Blank CU, Teng MWL.

Oncoimmunology. 2018 Nov 22;8(2):e1546068. doi: 10.1080/2162402X.2018.1546068. eCollection 2019.

47.

Prediction of implantation after blastocyst transfer in in vitro fertilization: a machine-learning perspective.

Blank C, Wildeboer RR, DeCroo I, Tilleman K, Weyers B, de Sutter P, Mischi M, Schoot BC.

Fertil Steril. 2019 Feb;111(2):318-326. doi: 10.1016/j.fertnstert.2018.10.030. Epub 2019 Jan 2.

PMID:
30611557
48.

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi ACJ, van den Braber M, Rozeman EA, Haanen JBAG, Blank CU, Horlings HM, David E, Baran Y, Bercovich A, Lifshitz A, Schumacher TN, Tanay A, Amit I.

Cell. 2019 Feb 7;176(4):775-789.e18. doi: 10.1016/j.cell.2018.11.043. Epub 2018 Dec 27.

49.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C.

Eur J Cancer. 2019 Jan;107:175-185. doi: 10.1016/j.ejca.2018.11.018. Epub 2018 Dec 20.

PMID:
30580112
50.

Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy.

Batzner A, Pfeiffer B, Neugebauer A, Aicha D, Blank C, Seggewiss H.

J Am Coll Cardiol. 2018 Dec 18;72(24):3087-3094. doi: 10.1016/j.jacc.2018.09.064.

Supplemental Content

Support Center